dc.contributor.author | Abdulbasit, Abdulmajd | |
dc.date.accessioned | 2020-07-07T10:14:13Z | |
dc.date.available | 2020-07-07T10:14:13Z | |
dc.date.issued | 2020-02-25 | |
dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/1741 | |
dc.description | Systemic lupus erythematosus (SLE) is an autoimmune disorder affecting multiple
organ systems including kidney, skin, lung, heart, the hematopoietic system and brain,
Glomerulonephritis (GN) is a term used to refer to several kidney diseases (usually
affecting both kidneys). Many of the diseases are characterized by inflammation
either of the glomeruli or of the small blood vessels in the kidneys, also
Glomerulonephritis leading to severe persistent proteinuria, chronic renal failure and
end-stage renal disease which remains one of the most severe complications of SLE
and its associated with significant morbidity and mortality. | en_US |
dc.description.abstract | A combination of systemic autoimmunity and tissue response to immune injury
underlie renal involvement in lupus erythematosus. In lupus glomerulonephritis,
glomerular immune complexes were believed to be the primary mediators of renal
disease. Recent studies make it apparent that autoantibodies of multiple specificities
participate in the formation of immune complexes, deposited in the kidneys. Renal
infiltration by T cells, macrophages, and dendritic cells have a dominant role in the
progression of lupus glomerulonephritis leading to renal failure. Activation of Tolllike receptors modulates autoantibody production and systemic interferon responses.
However, glomerular cell responses to immune injury influence disease outcome. In
addition, new insights on the genetics of susceptibility to end-organ damage in lupus
glomerulonephritis have been discovered. Lupus glomerulonephritis is a prototype of
immune complex disease mediated by autoantibodies of multiple specificities, one of
which is anti-DNA. Murine models of spontaneous systemic lupus erythematosus
have been critical for understanding the underlying disease. Recent studies
demonstrate that in addition to systemic autoimmunity, end-organ responses, and endorgan resistance to damage are also critical in determining disease outcome. This
understanding should influence design of novel therapeutic approaches in systemic
lupus erythematosus | en_US |
dc.language.iso | en | en_US |
dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | Systemic Lupus erythromatosis associated Glomerular Diseases | en_US |
dc.type | Other | en_US |